The present disclosure provides antibodies that bind to the prolactin receptor (PRLR), nucleic acids encoding the antibodies, methods of production using host cells, and its applications, including applications in pharmaceutical compositions for the treatment of PRLR-associated diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides antibodies that bind to the prolactin receptor (PRLR), nucleic acids encoding the antibodies, methods of production using host cells, and its applications, including applications in pharmaceutical compositions for the treatment of PRLR-associated diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
G06N 3/00 - Computing arrangements based on biological models
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
4.
EXPRESSION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS
C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 15/67 - General methods for enhancing the expression
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Described herein is a method of determining affinity of an antigen binding protein binding to a target, the method comprising: a) expressing an antigen binding protein in a prokaryotic host cell in a multi-well container, b) lysing the prokaryotic cell to produce a prokaryotic cell lysate; c) affixing the prokaryotic cell lysate to a substrate; and d) determining the affinity of the antigen binding protein to the target.
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments. Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments.
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments. Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological preparations for medical research purposes; Cells for medical or clinical use; antibodies for the treatment of inflammatory and fibrotic diseases. Medical and scientific research in the field of antibodies.
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological preparations for research use Biological preparations for medical purposes; cells for medical or clinical use; antibodies for medical purposes, namely, antibodies for the treatment of inflammatory and fibrotic diseases Medical and scientific research in the field of antibodies
11.
UNLOCKING DE NOVO ANTIBODY DESIGN WITH GENERATIVE ARTIFICIAL INTELLIGENCE
A computing system for generating structural information of a biomolecule includes a processor; and one or more non-transitory computer-readable media having stored thereon instructions that, when executed by the one or more processors, cause the computing system to: receive training inputs; process the training inputs with a machine-learned biomolecule prediction model; evaluate a loss function; and modify parameters of the machine-learned model. A computing system for generating structural information of a target biomolecule includes a processor and one or more non-transitory computer-readable media having stored thereon a machine-learned biomolecule prediction model and instructions that, when executed by the one or more processors, cause the computing system to receive a target input; and predict the structural information of the target biomolecule. A computing system for predicting an affinity of a target biomolecule includes a processor and a computer-readable media having stored thereon: a machine-learned affinity prediction artificial neural network, including: (i) one or more biomolecule prediction layers trained to predict biomolecule structural information from target inputs; (ii) one or more docking layers trained to generate docked complexes from two or more input three-dimensional biomolecules; and (iii) one or more affinity prediction layers trained to predict affinity from input docked complexes; wherein the one or more biomolecule prediction layers, the one or more docking layers, and the one or more affinity prediction layers are connected; and instructions that, when executed by the one or more processors, cause the computing system to: receive a target input; and process the target input using the affinity prediction artificial neural network to generate a docked complex corresponding to the target input and a corresponding structural affinity value.
The present disclosure provides materials and assays, herein referred to as surface display ACE (surfACE), that use E. coli strains expressing, in one embodiment, nanobodies (VHHs) on the outer cell membrane as a solution to increase de novo screening throughput and efficiency using a combination of MACS and FACS based enrichment strategies.
Fc domain variants having altered binding affinity for human FcRn, and polypeptides comprising the Fc domain variants. Also provided herein are nucleic acid encoding Fc domain variants or the polypeptides comprising the Fc domain variants, host cells comprising the encoding nucleic acid for making the variants or polypeptides, and methods for increasing the half-life of a polypeptide and using polypeptides comprising the Fc domain variants to treat disease.
The present disclosure relates HER2 antibodies and to the de novo design of structure-based design targeted antibodies. According to the current disclosure, computer-implemented methods of designing an antibody sequences that will bind the HER2 with significant affinity at a target receptor epitope are disclosed. The method utilizes artificial intelligence (Al) and machine learning (ML) models that are trained to predict improved biomolecule (e.g., antibody or antibody fragments) binding sequences or other desirable properties using known biomolecule/binding partner complexes. A designed HER2 antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
biological preparations for medical research purposes, namely, inflammatory and fibrotic diseases research; cells for medical or clinical use; antibodies for the treatment of inflammatory and fibrotic diseases in the nature of antibodies for medical purposes medical and scientific research in the field of antibodies
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
biological preparations for medical research purposes, namely, inflammatory and fibrotic diseases, genetic diseases, hormonal diseases, lifestyle research; cells for medical or clinical use; antibodies for the treatment of inflammatory and fibrotic diseases in the nature of antibodies for medical purposes medical and scientific research in the field of antibodies
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services in the nature of custom biomanufacturing of pharmaceutical preparations, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services in the nature of custom biomanufacturing of pharmaceutical preparations, namely, custom production of cell lines to produce proteins, namely, hormones, cytokines, antibodies and antibody fragments Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; biotechnical and pharmacological laboratory services for biomanufacturing, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research, namely, scientific research, development, analysis, producing, testing, in the field of biotechnology, namely, production of biotechnological products for use in preparing pharmaceutical preparations, and scientific research consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; development of pharmaceutical preparations, medicines and medicaments; technological consultancy services, namely, technological consultation in the field of biotechnology, namely, production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; development of pharmaceutical preparations in the nature of computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, development of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, development of cell lines to produce proteins, namely, hormones, cytokines, antibodies and antibody fragments
22.
TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
23.
TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
24.
TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
25.
TL1A associated antibody compositions and methods of use
The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
26.
SYSTEMS AND METHODS OF DEVELOPING DISEASE ASSOCIATED ANTIBODY SEQUENCES
The disclosure herein relates to in silico methods for reconstructing complete polypeptide and nucleic acid consensus sequences for novel biologically active protein dimers, including but not limited to antibodies that are useful for the treatment and diagnosis of a cancer, autoimmune condition, or infectious disease.
The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
28.
HIGH-THROUGHPUT METHODS FOR KINETIC CHARACTERIZATION, QUANTIFYING AND OPTIMIZING ANTIBODIES AND ANTIBODY FRAGMENTS EXPRESSION IN BACTERIA
Described herein is a method of determining affinity of an antigen binding protein binding to a target, the method comprising: a) expressing an antigen binding protein in a prokaryotic host cell in a multi-well container, b) lysing the prokaryotic cell to produce a prokaryotic cell lysate; c) affixing the prokaryotic cell lysate to a substrate; and d) determining the affinity of the antigen binding protein to the target. Also described herein are methods, reagents, principles, and strategies for engineering synthetic tags at optimal locations on an antigen binding protein (e.g., a VHH) to allow for efficient capture from lysate and high-throughput collection of kinetic binding data. A method of quantifying the expression of an antigen binding protein in a prokaryotic cell lysate and a method for screening optimal conditions for its expression are also disclosed.
An antigen-aware antibody folding computing system includes a processor and a memory having stored thereon a trained machine-learned model and instructions that, when executed, cause the system to receive input biomolecule digital representations and process the input using the model to generate predicted output biomolecule digital representations. A method includes receiving input biomolecule digital representations and processing the input using a trained machine-learned model to generate predicted output biomolecule digital representations. A non-transitory computer-readable storage medium includes a trained machine-learned model and instructions that, when executed, cause a computer to: receive input biomolecule digital representations and process the input using the machine-learned model to generate predicted output biomolecule digital representations.
Variant or mutant prokaryotic cells are disclosed that express elevated or increased levels of a wide variety of active proteins. Also disclosed are methods of producing the elevated or increased levels of active encoded proteins.
The present disclosure provides compositions and methods for identifying a host cell or host cells from a population of cells that produce a gene product of interest. The present disclosure further provides a solid-phase screening workflow that enables affinity determination and the identification of high-producing strains.
The present disclosure provides compositions and methods for identifying cells or strains that produce soluble protein. The present disclosure further provides a growth/no growth selection strategy to identify E. coli strains in a mixed population (library) that produce higher soluble protein.
The disclosure provides products and methods for the heterologous expression of proteins in host cells. The provided expression constructs, bacterial cells and methods produce a PnlP-1 accessory protein that increases the yield of a heterologous protein of interest.
The present disclosure provides compositions and methods for identifying and recovering a host cell or host cells from a population of cells that produce a gene product of interest. The present disclosure further provides a solid-phase screening workflow that enables affinity determination and the identification of high-producing strains.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
35.
COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS
This disclosure provides engineered tRNAs and the corresponding aminoacyl tRNA synthetase for efficient production of proteins containing non-standard amino acids. These engineered orthogonal tRNA (O-tRNA)/orthogonal aminoacyl tRNA synthetase (O-RS) pair, i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.
A method includes generating one or more DNA sequences using a machine learning model using coding sequences; comparing the DNA sequences to one or more natural DNA sequences; and determining a codon naturalness. A computing system includes a processor; and a memory having stored thereon computer-executable instructions that, when executed by the one or more processors, cause the computing system to: generate one or more DNA sequences using a machine learning model using coding sequences; compare the DNA sequences to one or more natural DNA sequences; and determine a codon naturalness. A non-transitory computer¬ readable medium has stored thereon instructions that, when executed by one or more processors, cause a computer to: generate one or more DNA sequences using a machine learning model using coding sequences; compare the DNA sequences to one or more natural DNA sequences; and determine a codon naturalness.
The present disclosure generally relates to methods of rapidly and efficiently searching biologically-related data space. More specifically, the disclosure includes methods of identifying biomolecules with desired properties, or which are most suitable for acquiring such properties, from complex biomolecule libraries or sets of such libraries. The disclosure also provides methods of modeling sequence-activity relationships. The disclosure further relates to methods for generating training data for training a machine learning model to predict biomolecule gene sequences with desired properties. Methods of the present disclosure have utility in the optimization of proteins for industrial and therapeutic use.
Methods, systems and computer-readable media for identifying optimized cell media formulations capable of promoting the expression of a biomolecule of interest are presented, which may include applying mixing algorithms, culturing cells, and measuring component conditions. The techniques may include identifying genes and/or or more independently modulated gene sets. The present techniques include methods, systems and computer-readable media for improving quality of monoclonal antibodies.
Described herein is a method of determining affinity of an antigen binding protein binding to a target, the method comprising: a) expressing an antigen binding protein in a prokaryotic host cell in a multi-well container, b) lysing the prokaryotic cell to produce a prokaryotic cell lysate; c) affixing the prokaryotic cell lysate to a substrate; and d) determining the affinity of the antigen binding protein to the target.
This disclosure provides engineered aminoacyl tRNA synthetases and tRNAs for efficient production of proteins containing non-standard amino acids. These engineered orthogonal tRNA (O-tRNA)/orthogonal aminoacyl tRNA synthetase (O-RS) pairs, i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.
A delayed inoculation test tube device includes a container comprising an elongated annular wall disposed along a central longitudinal axis, an access opening disposed at a top portion of the container, and a bottom wall disposed at a bottom portion of the container. The access opening of the container in fluid communication with a hollow cylindrical cavity defined between the elongated annular wall and the bottom wall. The receptacle further includes an aperture defined by the container and extending through the elongated annular wall or the bottom wall. Further, the receptacle may include a window disposed in the aperture, the window comprising a soluble material.
The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin.
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
45.
SARS-COV-2 ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
The disclosure herein relates to novel antibodies and antigen binding fragments that are used in the treatment, prevention and diagnosis of COVID-19, the disease caused by SARS-CoV-2. The complete polypeptide and nucleic acid consensus sequences of the antibodies and antigen binding fragments disclosed herein are reconstructed in silico.
i.e.i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.
A computing system includes a processor and a memory having stored thereon a trained machine-learned model and instructions that, when executed by the one or more processors, cause the computing system to process a biomolecule sequence variant to predict binding characteristics, identify biomolecule sequence variants of interest; and provide the biomolecule sequence variants of interest as output. A computer-implemented method for training a machine learning model to identify biomolecule sequence variants of interest includes generating biomolecule sequence variants, receiving screening data; and training the machine learning model to predict binding characteristics of an input biomolecule sequence variant. A computing system includes a processor; and a non-transitory computer-readable media having stored thereon a machine-learned model trained using training data and instructions that, when executed by the one or more processors, cause the computing system to: process one or more input biomolecule sequence variants; and provide a predicted naturalness characteristics as output.
A computing system for generating structural information of a biomolecule includes a processor; and one or more non-transitory computer-readable media having stored thereon instructions that, when executed by the one or more processors, cause the computing system to: receive training inputs; process the training inputs with a machine-learned biomolecule prediction model; evaluate a loss function; and modify parameters of the machine-learned model. A computing system for generating structural information of a target biomolecule includes a processor and one or more non-transitory computer-readable media having stored thereon a machine-learned biomolecule prediction model and instructions that, when executed by the one or more processors, cause the computing system to receive a target input; and predict the structural information of the target biomolecule.
G06F 16/2457 - Query processing with adaptation to user needs
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
A computing system for generating structural information of a biomolecule includes a processor; and one or more non-transitory comput¬ er-readable media having stored thereon instructions that, when executed by the one or more processors, cause the computing system to: receive training inputs; process the training inputs with a machine-learned biomolecule pre¬ diction model; evaluate a loss function; and modify parameters of the ma¬ chine-learned model. A computing system for generating structural informa¬ tion of a target biomolecule includes a processor and one or more non-transito¬ ry computer-readable media having stored thereon a machine-learned biomol¬ ecule prediction model and instructions that, when executed by the one or more processors, cause the computing system to receive a target input; and predict the structural information of the target biomolecule. A computing system for predicting an affinity of a target biomolecule includes a processor and a com¬ puter-readable media having stored thereon: a machine-learned affinity predic¬ tion artificial neural network, including: (i) one or more biomolecule prediction layers trained to predict biomolecule structural information from target inputs; (ii) one or more docking layers trained to generate docked complexes from two or more input three-dimensional biomolecules; and (iii) one or more affin¬ ity prediction layers trained to predict affinity from input docked complexes; wherein the one or more biomolecule prediction layers, the one or more dock¬ ing layers, and the one or more affinity prediction layers are connected; and instructions that, when executed by the one or more processors, cause the com¬ puting system to: receive a target input; and process the target input using the affinity prediction artificial neural network to generate a docked complex cor¬ responding to the target input and a corresponding structural affinity value.
G06F 16/2457 - Query processing with adaptation to user needs
G06K 19/06 - Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
A computing system includes a processor and a memory having stored thereon a trained machine-learned model and instructions that, when executed by the one or more processors, cause the computing system to process a biomolecule sequence variant to predict binding characteristics, identify biomolecule sequence variants of interest; and provide the biomolecule sequence variants of interest as output. A computer-implemented method for training a machine learning model to identify biomolecule sequence variants of interest includes generating biomolecule sequence variants, receiving screening data; and training the machine learning model to predict binding characteristics of an input biomolecule sequence variant. A computing system includes a processor; and a non-transitory computer-readable media having stored thereon a machine-learned model trained using training data and instructions that, when executed by the one or more processors, cause the computing system to: process one or more input biomolecule sequence variants; and provide a predicted naturalness characteristics as output.
A computing system includes a processor and a memory having stored thereon a trained machine-learned model and instructions that, when executed by the one or more processors, cause the computing system to process a biomolecule sequence variant to predict binding characteristics, identify biomolecule sequence variants of interest; and provide the biomolecule sequence variants of interest as output. A computer-implemented method for training a machine learning model to identify biomolecule sequence variants of interest includes generating biomolecule sequence variants, receiving screening data; and training the machine learning model to predict binding characteristics of an input biomolecule sequence variant. A computing system includes a processor; and a non-transitory computer-readable media having stored thereon a machine-learned model trained using training data and instructions that, when executed by the one or more processors, cause the computing system to: process one or more input biomolecule sequence variants; and provide a predicted naturalness characteristics as output.
Variant or mutant prokaryotic cells are disclosed that express elevated or increased levels of a wide variety of active proteins. Also disclosed are methods of producing the elevated or increased levels of active encoded proteins.
The present disclosure provides compositions and methods for identifying cells or strains that produce soluble protein. The present disclosure further provides a growth/no growth selection strategy to identify E. coll strains in a mixed population (library) that produce higher soluble protein.
The present disclosure provides compositions and methods for identifying cells or strains that produce soluble protein. The present disclosure further provides a growth/no growth selection strategy to identify E. coll strains in a mixed population (library) that produce higher soluble protein.
C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
C12N 15/67 - General methods for enhancing the expression
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
56.
PRODUCTS AND METHODS FOR HETEROLOGOUS EXPRESSION OF PROTEINS IN A HOST CELL
The disclosure provides products and methods for the heterologous expression of proteins in host cells. The provided expression constructs, bacterial cells and methods produce a PnlP-1 accessory protein that increases the yield of a heterologous protein of interest.
C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/67 - General methods for enhancing the expression
57.
PRODUCTS AND METHODS FOR HETEROLOGOUS EXPRESSION OF PROTEINS IN A HOST CELL
The disclosure provides products and methods for the heterologous expression of proteins in host cells. The provided expression constructs, bacterial cells and methods produce a PnlP-1 accessory protein that increases the yield of a heterologous protein of interest.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)
C12N 15/67 - General methods for enhancing the expression
58.
SOLID-PHASE SCREENING FOR HIGH-PERFORMING BACTERIAL STRAINS
The present disclosure provides compositions and methods for identifying a host cell or host cells from a population of cells that produce a gene product of interest. The present disclosure further provides a solid-phase screening workflow that enables affinity determination and the identification of high-producing strains.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
59.
SOLID-PHASE SCREENING FOR HIGH-PERFORMING BACTERIAL STRAINS
The present disclosure provides compositions and methods for identifying a host cell or host cells from a population of cells that produce a gene product of interest. The present disclosure further provides a solid-phase screening workflow that enables affinity determination and the identification of high-producing strains.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
60.
MEMBRANE-ASSOCIATED FUSION PROTEINS TO INCREASE THE COMPETENCY OF CELLS
The present disclosure provides compositions and methods for using membrane- associated fusion proteins to increase competency of cells. Described herein are fusion proteins comprising membrane-associated proteins and nucleic acid-binding proteins.
C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
C12N 15/62 - DNA sequences coding for fusion proteins
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
62.
COMPOSITION OF TRANSFER RNAS AND USE IN PRODUCTION OF PROTEINS CONTAINING NON-STANDARD AMINO ACIDS
This disclosure provides engineered tRNAs and the corresponding aminoacyl tRNA synthetase for efficient production of proteins containing non-standard amino acids. These engineered orthogonal tRNA (O-tRNA) / orthogonal aminoacyl tRNA synthetase (O-RS) pair, i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.
i.e.i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.
The present disclosure provides assay methods for the detection and/or quantification of an analyte in a sample. In some examples, the methods detect and/or quantify an active analyte in a sample.
G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
A connecting polypeptide has SEQ ID NO:73. A proinsulin polypeptide includes a mature insulin A-chain, a mature insulin B-chain, and a connecting peptide comprising SEQ ID NO: 73 linking the mature A-chain and the mature B-chain, wherein the connecting peptide is not a native human proinsulin C-peptide. The proinsulin polypeptides according to the invention can be made in high titers and in high purity.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
An activity-specific cell-enrichment method, capable of selection of high-performing host cells and/or expression vectors from a genetically diverse pool of host cells that can comprise expression vectors is provided.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, hereunder, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, hereunder, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, hereunder, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; bioinformatics research services, hereunder, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; biotechnological services, hereunder, discovery, production, and purification of biotechnological and pharmaceutical preparations, hereunder, hormones, antibodies, and proteins; biotechnological services, hereunder, discovery and production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, hereunder, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, hereunder, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, hereunder, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; bioinformatics research services, hereunder, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; biotechnological services, hereunder, discovery, production, and purification of biotechnological and pharmaceutical preparations, hereunder, hormones, antibodies, and proteins; biotechnological services, hereunder, discovery and production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Biological preparations for preparing proteins for industrial purposes; and biological cells for medical research purposes biological preparations for medical research purposes
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biological preparations for preparing proteins for industrial purposes. Biological preparations for medical research purposes; biological cells for medical research purposes. Scientific research; medical research.
71.
Cancer associated antibody compositions and methods of use
The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, custom production and purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, custom production of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; discovery of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations; Bioinformatics research services, namely, analyzing complex biological data through the use of artificial intelligence, and testing and evaluation of biologics through artificial intelligence; computer assisted biologics design involving the use of artificial intelligence technology; Biotechnological services, namely, discovery of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; biotechnological services, namely, discovery of cell lines to produce proteins, such as hormones, cytokines, antibodies and antibody fragments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations
76.
Cancer associated antibody compositions and methods of use
The disclosure herein relates to novel cancer-associated antibodies that are used in the treatment and diagnosis of a cancer. The complete polypeptide and nucleic acid consensus sequences of the antibodies disclosed herein are reconstructed in silico.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/26 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure provides assay methods for the detection and/or quantification of an analyte in a sample. In some examples, the methods detect and/or quantify an active analyte in a sample.
An activity-specific cell-enrichment method, capable of selection of high-performing host cells and/or expression vectors from a genetically diverse pool of host cells that can comprise expression vectors is provided.
A cell for producing insulin includes an E. coli host cell and a polynucleotide designed for production of insulin disposed within the E. coli host cell. The polynucleotide includes a first inducible promoter and a first coding sequence to be transcribed from the first inducible promoter, the first coding sequence encoding an insulin polypeptide. The polynucleotide also includes a second inducible promoter and a second coding sequence to be transcribed from the second inducible promoter, the second coding sequence encoding one or more of cDsbA, cDsbC, a protein disulfide isomerase, Ervlp, and a chaperone. The first inducible promoter and the second inducible promoter are not responsive to the same inducer. A method of producing insulin includes growing a sample of the cells in a fermentation volume between 0.1 L and 1,000,000 L, adding an inducer of the first inducible promoter to induce expression of the insulin polypeptide, and purifying the insulin polypeptide.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
80.
Host cells for use in an inducible coexpression system
The present invention provides host cells for use in an inducible coexpression system that is capable of controlled induction of expression of each gene product.
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
81.
CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
The disclosure herein relates to novel cancer-associated antibodies that are used in the treatment and diagnosis of a cancer. The complete polypeptide and nucleic acid consensus sequences of the antibodies disclosed herein are reconstructed in silico.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, purification of
biotechnological and pharmaceutical preparations, namely,
hormones, antibodies, and proteins. Scientific and technological consulting services relating to
producing, assaying, and purifying biotechnological
products; research and development in the pharmaceutical and
biotechnology fields; services of biotechnical and
pharmacological laboratories, namely, scientific and
technological research relating to the production of
biotechnological products for use in preparing
pharmaceutical preparations; scientific and technological
research relating to the production of biotechnological
products for use in preparing pharmaceutical preparations,
and scientific consultation related thereto; scientific
research, namely, carrying out feasibility studies relating
to the production of biotechnological products for use in
preparing pharmaceutical preparations; development of
pharmaceutical preparations, medicines and medicaments;
technological services, namely, technological consultation
relating to the production of biotechnological products for
use in preparing pharmaceutical preparations.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation and relating to the production of biotechnological products for use in preparing pharmaceutical preparations.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific and technical consulting services relating to producing, assaying, and purifying biotechnological products; biotechnological services, namely, purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins; scientific research; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation and relating to the production of biotechnological products for use in preparing pharmaceutical preparations.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Scientific research; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Biotechnological services, namely, purification of biotechnological and pharmaceutical preparations, namely, hormones, antibodies, and proteins Scientific and technological consulting services relating to producing, assaying, and purifying biotechnological products; research and development in the pharmaceutical and biotechnology fields; services of biotechnical and pharmacological laboratories, namely, scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations; scientific and technological research relating to the production of biotechnological products for use in preparing pharmaceutical preparations, and scientific consultation related thereto; scientific research, namely, carrying out feasibility studies relating to the production of biotechnological products for use in preparing pharmaceutical preparations; development of pharmaceutical preparations, medicines and medicaments; technological services, namely, technological consultation relating to the production of biotechnological products for use in preparing pharmaceutical preparations
The present invention provides host cells having an oxidizing cytoplasm, which are capable of growing to high cell densities and producing recombinant proteins in soluble form. Also provided are methods for growing such host cells to high densities, methods for optionally modulating the growth rates of the host cells, and methods for inducing the host cells to produce the desired gene product in soluble form. Further aspects of the invention relate to host cell preparation and storage methods, which utilize the advantages of producing gene products in host cell cytoplasm to provide methods for long-term storage and/or transport of expressed gene products that are retained in a stable and soluble form within the host cells.
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides host cells for use in an inducible coexpression system that is capable of controlled induction of expression of each gene product.
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
90.
Vectors for use in an inducible coexpression system
The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product.
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12P 21/04 - Cyclic or bridged peptides or polypeptides, e.g. bacitracin
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
